DevaCell’s ONCoat™ synthetic vector-based platform technology is enabling transformative, new therapeutic opportunities across three key segments: Oncolytic virus therapy, vaccines and gene therapy/gene editing application. The company’s lead therapeutic program is focused on applying our novel synthetic vector technology to oncolytic viral therapy. Our synthetic vector-based immunotherapeutics are designed to activate and enhance a patient’s own immune system, which enable the potential to dramatically improve patient outcomes.